Literature DB >> 21119647

Commentary: Early antiretroviral therapy for HIV infection in sub-Saharan Africa, a challenging new step.

Christian Laurent1.   

Abstract

Recent changes in guidelines (World Health Organization (WHO), USA, and likely Europe soon) all move towards earlier initiation of antiretroviral therapy in asymptomatic patients infected with human immunodeficiency virus (HIV). Sonia Menon appropriately questions the feasibility and consequences at both individual and community levels of the early initiation of antiretroviral therapy in sub-Saharan Africa as likely effects will be both positive and negative. Local context should drive the uptake process in every country. Money, national and international, will be essential for the successful implementation of the new WHO recommendation. Leaders at both levels must take their responsibilities and mobilize the necessary resources, for example, doubling those for the Global Fund to Fight AIDS, Tuberculosis and Malaria from $10 billion to $20 billion USD for 2011-2013.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21119647     DOI: 10.1057/jphp.2010.36

Source DB:  PubMed          Journal:  J Public Health Policy        ISSN: 0197-5897            Impact factor:   2.222


  2 in total

1.  Mortality, AIDS-morbidity, and loss to follow-up by current CD4 cell count among HIV-1-infected adults receiving antiretroviral therapy in Africa and Asia: data from the ANRS 12222 collaboration.

Authors:  Delphine Gabillard; Charlotte Lewden; Ibra Ndoye; Raoul Moh; Olivier Segeral; Besigin Tonwe-Gold; Jean-François Etard; Men Pagnaroat; Isabelle Fournier-Nicolle; Serge Eholié; Issouf Konate; Albert Minga; Eitel Mpoudi-Ngole; Sinata Koulla-Shiro; Djimon Marcel Zannou; Xavier Anglaret; Christian Laurent
Journal:  J Acquir Immune Defic Syndr       Date:  2013-04-15       Impact factor: 3.731

Review 2.  Inpatient mortality of HIV-infected adults in sub-Saharan Africa and possible interventions: a mixed methods review.

Authors:  Bahati Mk Wajanga; Lauren E Webster; Robert N Peck; Jennifer A Downs; Kedar Mate; Luke R Smart; Daniel W Fitzgerald
Journal:  BMC Health Serv Res       Date:  2014-12-03       Impact factor: 2.655

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.